The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
Background: chronic kidney disease (CKD) and non-alcoholic fatty liver disease (NAFLD) frequently co-exist. We assess the impact of having NAFLD on adverse clinical outcomes and all-cause mortality for people with CKD.
Methods: a total of 18,073 UK Biobank participants identified to have CKD (eGFR < 60 ml/min/1.73 m 2 or albuminuria > 3 mg/mmol) were prospectively followed up by electronic linkage to hospital and death records. Cox-regression estimated the hazard ratios (HR) associated with having NAFLD (elevated hepatic steatosis index or ICD-code) and NAFLD fibrosis (elevated fibrosis-4 (FIB-4) score or NAFLD fibrosis score (NFS)) on cardiovascular events (CVE), progression to end-stage renal disease (ESRD) and all-cause mortality.
Results: 56.2% of individuals with CKD had NAFLD at baseline, and 3.0% and 7.7% had NAFLD fibrosis according to a FIB-4 > 2.67 and NFS ≥ 0.676, respectively. The median follow-up was 13 years. In univariate analysis, NAFLD was associated with an increased risk of CVE (HR 1.49 [1.38–1.60]), all-cause mortality (HR 1.22 [1.14–1.31]) and ESRD (HR 1.26 [1.02–1.54]). Following multivariable adjustment, NAFLD remained an independent risk factor for CVE overall (HR 1.20 [1.11–1.30], p < 0.0001), but not ACM or ESRD. In univariate analysis, elevated NFS and FIB-4 scores were associated with increased risk of CVE (HR 2.42 [2.09–2.80] and 1.64 [1.30–2.08]) and all-cause mortality (HR 2.82 [2.48–3.21] and 1.82 [1.47–2.24]); the NFS score was also associated with ESRD (HR 5.15 [3.52–7.52]). Following full adjustment, the NFS remained associated with an increased incidence of CVE (HR 1.19 [1.01–1.40]) and all-cause mortality (HR 1.31 [1.13–1.52]).
Conclusions: in people with CKD, NAFLD is associated with an increased risk of CVE, and the NAFLD fibrosis score is associated with an elevated risk of CVE and worse survival.
Cardiovascular disease, Chronic kidney disease, Multi-morbidity, Non-alcoholic fatty liver disease
Hydes, Theresa
d842d1ec-c64a-4934-a5a2-7316fea65767
Kennedy, Oliver
96f5e8fc-f18e-4887-8504-77ffef83c7f1
Buchanan, Ryan
9499f713-f684-4046-be29-83cd9d6f834d
Cuthbertson, Daniel J
806220c4-ce38-4337-babf-93d6fdded669
Parkes, Julie
59dc6de3-4018-415e-bb99-13552f97e984
Fraser, Simon
135884b6-8737-4e8a-a98c-5d803ac7a2dc
Roderick, Paul
dbb3cd11-4c51-4844-982b-0eb30ad5085a
18 May 2023
Hydes, Theresa
d842d1ec-c64a-4934-a5a2-7316fea65767
Kennedy, Oliver
96f5e8fc-f18e-4887-8504-77ffef83c7f1
Buchanan, Ryan
9499f713-f684-4046-be29-83cd9d6f834d
Cuthbertson, Daniel J
806220c4-ce38-4337-babf-93d6fdded669
Parkes, Julie
59dc6de3-4018-415e-bb99-13552f97e984
Fraser, Simon
135884b6-8737-4e8a-a98c-5d803ac7a2dc
Roderick, Paul
dbb3cd11-4c51-4844-982b-0eb30ad5085a
Hydes, Theresa, Kennedy, Oliver, Buchanan, Ryan, Cuthbertson, Daniel J, Parkes, Julie, Fraser, Simon and Roderick, Paul
(2023)
The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank.
BMC Medicine, 21 (1), [185].
(doi:10.1186/s12916-023-02891-x).
Abstract
Background: chronic kidney disease (CKD) and non-alcoholic fatty liver disease (NAFLD) frequently co-exist. We assess the impact of having NAFLD on adverse clinical outcomes and all-cause mortality for people with CKD.
Methods: a total of 18,073 UK Biobank participants identified to have CKD (eGFR < 60 ml/min/1.73 m 2 or albuminuria > 3 mg/mmol) were prospectively followed up by electronic linkage to hospital and death records. Cox-regression estimated the hazard ratios (HR) associated with having NAFLD (elevated hepatic steatosis index or ICD-code) and NAFLD fibrosis (elevated fibrosis-4 (FIB-4) score or NAFLD fibrosis score (NFS)) on cardiovascular events (CVE), progression to end-stage renal disease (ESRD) and all-cause mortality.
Results: 56.2% of individuals with CKD had NAFLD at baseline, and 3.0% and 7.7% had NAFLD fibrosis according to a FIB-4 > 2.67 and NFS ≥ 0.676, respectively. The median follow-up was 13 years. In univariate analysis, NAFLD was associated with an increased risk of CVE (HR 1.49 [1.38–1.60]), all-cause mortality (HR 1.22 [1.14–1.31]) and ESRD (HR 1.26 [1.02–1.54]). Following multivariable adjustment, NAFLD remained an independent risk factor for CVE overall (HR 1.20 [1.11–1.30], p < 0.0001), but not ACM or ESRD. In univariate analysis, elevated NFS and FIB-4 scores were associated with increased risk of CVE (HR 2.42 [2.09–2.80] and 1.64 [1.30–2.08]) and all-cause mortality (HR 2.82 [2.48–3.21] and 1.82 [1.47–2.24]); the NFS score was also associated with ESRD (HR 5.15 [3.52–7.52]). Following full adjustment, the NFS remained associated with an increased incidence of CVE (HR 1.19 [1.01–1.40]) and all-cause mortality (HR 1.31 [1.13–1.52]).
Conclusions: in people with CKD, NAFLD is associated with an increased risk of CVE, and the NAFLD fibrosis score is associated with an elevated risk of CVE and worse survival.
Text
s12916-023-02891-x
- Version of Record
More information
Accepted/In Press date: 4 May 2023
e-pub ahead of print date: 18 May 2023
Published date: 18 May 2023
Additional Information:
Funding Information:
None.
Publisher Copyright:
© 2023, The Author(s).
Keywords:
Cardiovascular disease, Chronic kidney disease, Multi-morbidity, Non-alcoholic fatty liver disease
Identifiers
Local EPrints ID: 477415
URI: http://eprints.soton.ac.uk/id/eprint/477415
ISSN: 1741-7015
PURE UUID: 81b88e65-8f37-4ea9-a8f4-72707deea8ea
Catalogue record
Date deposited: 06 Jun 2023 16:52
Last modified: 06 Jun 2024 02:03
Export record
Altmetrics
Contributors
Author:
Theresa Hydes
Author:
Oliver Kennedy
Author:
Daniel J Cuthbertson
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics